taletrectinib
taletrectinib: developed by 1 company · 7 clinical trials tracked.
taletrectinib evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could taletrectinib → NUVB affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Nuvation Bio Inc. (NUVB) Non Small Cell Lung Cancer; Non-small Cell Lung Cancer (NSCL… | Phase 3 |
| Nuvation Bio Inc. (NUVB) Adult patients with locally advanced or metastatic ROS1-posi… | Approved |
Clinical Trials (7)
Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
An Open-label, Fixed Sequence Study to Evaluate the Effect of Famotidine on the Pharmacokinetics and Safety of Taletrectinib in Healthy Adult Participant
Primary endpoint: Cmax of Taletrectinib
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
Primary endpoint: Primary Outcome Measure: To compare the efficacy of taletrectinib with that of placebo, as measured by disease-free survival (DFS) by investigator assessment.
A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
Primary endpoint: PFS (Assessed by BIRC)
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Primary endpoint: Objective response rate (ORR) by independent radiology review committee (IRC)
A Phase II, Multicenter, Open, Basket Study of AB-106 to Treat the Subjects With Local Progression or Systemic Metastasis Solid Tumors With NTRK Gene Fusion
Primary endpoint: Objective response rate (ORR)
A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC
Primary endpoint: Best overall response (BOR) by IRC
Frequently asked questions
Who is developing taletrectinib?
taletrectinib is being developed by Nuvation Bio Inc..
How many clinical trials involve taletrectinib?
BioSniper tracks 7 clinical trials involving taletrectinib.